Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Clinical trial NCT04305054 · COMPLETED
Trial details
- NCT number
- NCT04305054
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-01
- Primary completion
- 2026-05-18
- Enrollment
- 335
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.